Coleman CI, et al. - In people with type 2 diabetes and proteinuria, researchers evaluated the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on renal and mortality results. For this investigation, they involved randomized trials of ≥ 100 candidates with type 2 diabetes and micro- or macroalbuminuria comparing an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker with placebo ± background anti-hypertensives or non-angiotensin-converting enzyme inhibitor or angiotensin receptor blocker-containing anti-hypertensives, which incorporated follow-up of ≥ 12 months. According to findings, the use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker was not linked to a significant reduction in the risk of a doubling in serum creatinine. Findings suggested that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can decrease the risk of end-stage renal disease and slow nephropathy progression, but they do not seem to reduce all-cause or cardiovascular mortality in individuals with type 2 diabetes and proteinuria. No distinction was noted with regard to all-cause or cardiovascular mortality, nor the composite result of duplication in serum creatinine, end-stage renal disease or mortality.